FUNDAMENTAL ASPECTS IN THE DEVELOPMENT OF MICROEMULSION SYSTEMS CONTAINING AMPHOTERICIN B FOR OPHTHALMIC USE
This is an overview of the development of microemulsion systems containing amphotericin B for ophthalmic use. The amphotericin B (AmB) is used to treat a fungal infection of eye and bioavailability of the AmB is the challenge for the research scientist. The poor bioavailability of AmB is due mainly to the corneal barrier, which eventually leads to a precorneal loss and subsequent decrease in the absorption of this drug into the intraocular tissues. Also, AmB has limited permeation across the intact corneal epithelium, which along with the toxicity associated with this molecule, epitomizes a major drawback to its clinical use. Therefore, new effective and safe drug vehicles for ocular delivery of AmB are urgently required. Recently, microemulsions (MEs) have been used in ophthalmic drug delivery system owing to their thermodynamic stability, transparent appearance, and favorable viscosity. Information and proper understanding of the physical chemistry and process of formation of AmB-containing MEs would provide reliable information on the best conditions for the use of these systems as eye drops. The aim of this research was thus to review the main studies on the use of MEs as delivery systems for AmB in topical eye treatment.
2. Parekh HB, Jivani R, Jivani N, Patel L, Makwana A, Sameja K, Novel insitu polymeric drug delivery system: a review, Journal of Drug Delivery and Therapeutics, 2012, 2(5).
3. Gaudana R, Jwala J, Boddu SH, Mitra AK, Recent perspectives in ocular drug delivery, Pharmaceutical research, 2009, 26(5), 1197-216.
4. Bonacucina G, Cespi M, Misiciâ€Falzi M, Palmieri GF, Colloidal soft matter as drug delivery system, Journal of pharmaceutical sciences, 2009, 98(1), 1-42.
5. Chaumeil C, Bourcier T, Rostane H, et al., Diagnosis and treatment of keratomycosis and fungal endophthalmitis, JOURNAL DE MYCOLOGIE MEDICALE, 2007, 17(2), 89-108.
6. Esposito E, Bortolotti F, Menegatti E, Cortesi R, Amphiphilic association systems for Amphotericin B delivery, International journal of pharmaceutics, 2003, 260(2), 249-60.
7. Wood T, Tuberville A, Monnett R, Keratomycosis and amphotericin B, Transactions of the American Ophthalmological Society, 1985, 83, 397.
8. Torrado J, Espada R, Ballesteros M, Torradoâ€Santiago S, Amphotericin B formulations and drug targeting, Journal of pharmaceutical sciences, 2008, 97(7), 2405-25.
9. Morand K, Bartoletti A, Bochot A, Barratt G, Brandely M, Chast F, Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability, International journal of pharmaceutics, 2007, 344(1), 150-3.
10. Kaji Y, Yamamoto E, Hiraoka T, Oshika T, Toxicities and pharmacokinetics of subconjunctival injection of liposomal amphotericin B, Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247(4), 549-53.
11. Mohan K, Pravin S, Atul B, Ophthalmic microemulsion: a comprehensive review, Int J Pharm Bio Sci, 2012, 3(3), 1-13.
12. Saini JK, Nautiyal U, Kumar M, Singh D, Anwar F, Microemulsions: A potential novel drug delivery system, International Journal of Pharmaceutical and Medicinal Research, 2014, 2(1), 15-20.
13. Hashem FM, Shaker DS, Ghorab MK, Nasr M, Ismail A, Formulation, characterization, and clinical evaluation of microemulsion containing clotrimazole for topical delivery, AAPS PharmSciTech, 2011, 12(3), 879-86.
14. Hegde RR, Verma A, Ghosh A, Microemulsion: new insights into the ocular drug delivery, ISRN pharmaceutics, 2013, 2013.
15. Vandamme TF, Microemulsions as ocular drug delivery systems: recent developments and future challenges, Progress in retinal and eye research, 2002, 21(1), 15-34.
16. Bottos KM, Oliveira AG, Bersanetti PA, et al., Corneal absorption of a new riboflavin-nanostructured system for transepithelial collagen cross-linking, PLoS one, 2013, 8(6), e66408.
17. Brime B, Moreno MA, Frutos G, Ballesteros M, Frutos P, Amphotericin B in oilâ€“water lecithinâ€based microemulsions: Formulation and toxicity evaluation, Journal of pharmaceutical sciences, 2002, 91(4), 1178-85.
18. Moreno MA, Frutos P, Ballesteros MP, Lyophilized lecithin based oil-water microemulsions as a new and low toxic delivery system for amphotericin B, Pharmaceutical research, 2001, 18(3), 344-51.
19. Pestana K, Formariz T, Franzini C, et al., Oil-in-water lecithin-based microemulsions as a potential delivery system for amphotericin B, Colloids and surfaces B: Biointerfaces, 2008, 66(2), 253-9.
20. Gupta S, Moulik S, Biocompatible microemulsions and their prospective uses in drug delivery, Journal of pharmaceutical sciences, 2008, 97(1), 22-45.
21. Fialho SL, Silvaâ€Cunha D, New vehicle based on a microemulsion for topical ocular administration of dexamethasone, Clinical & experimental ophthalmology, 2004, 32(6), 626-32.
22. Dwivedi C, Sahu R, Tiwari SP, Satapathy T, Roy A, Role of liposome in novel drug delivery system, Journal of Drug Delivery and Therapeutics, 2014, 4(2), 116-29.
23. Chaudhari SP, Dave RH, Investigating the Effect Of Molecular Weight of Polyvinylpyrrolidone and Hydroxypropyl Methyl Cellulose as Potential Antiprecipitants on Supersaturated Drug Solutions and Formulations using Weakly Acidic Drug: Indomethacin, International Journal of Pharmaceutical Sciences and Research, 2016, 7(10), 3931-48.
24. Tenjarla S, Microemulsions: an overview and pharmaceutical applications, Critical Reviewsâ„¢ in Therapeutic Drug Carrier Systems, 1999, 16(5).
25. Kaur IP, Rana C, Singh H, Development of effective ocular preparations of antifungal agents, Journal of Ocular Pharmacology and Therapeutics, 2008, 24(5), 481-94.
26. Muzaffar F, Singh U, Chauhan L, Review on microemulsion as futuristic drug delivery, Int J Pharm Pharm Sci, 2013, 5(3), 39-53.
27. Silva AE, Barratt G, ChÃ©ron M, Egito EST, Development of oil-in-water microemulsions for the oral delivery of amphotericin B, International journal of pharmaceutics, 2013, 454(2), 641-8.
28. Bouchemal K, BrianÃ§on S, Perrier E, Fessi H, Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation, International journal of pharmaceutics, 2004, 280(1), 241-51.
29. Damasceno BP, Dominici VA, Urbano IA, et al., Amphotericin B microemulsion reduces toxicity and maintains the efficacy as an antifungal product, Journal of biomedical nanotechnology, 2012, 8(2), 290-300.
30. Alany R, Rades T, Nicoll J, Tucker I, Davies N, W/O microemulsions for ocular delivery: Evaluation of ocular irritation and precorneal retention, Journal of controlled release, 2006, 111(1), 145-52.
31. Kumar JR, Muralidharan S, Parasuraman S, Antifungal agents: New approach for novel delivery systems, 2014.
32. Thomas PA, Current perspectives on ophthalmic mycoses, Clinical microbiology reviews, 2003, 16(4), 730-97.
33. Yamaguchi M, Yasueda S-i, Isowaki A, et al., Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate, International journal of pharmaceutics, 2005, 301(1), 121-8.
34. Chaudhari SP, Dave RH, Evaluating the Effects of Different Molecular Weights of Polymers in Stabilizing Supersaturated Drug Solutions and Formulations Using Various Methodologies of the Model Drug: Fenofibrate, Journal of Pharmaceutical Sciences and Pharmacology, 2015, 2(3), 259-76.
35. Kaushik S, Ram J, Brar GS, Jain AK, Chakraborti A, Gupta A, Intracameral amphotericin B: initial experience in severe keratomycosis, Cornea, 2001, 20(7), 715-9.
36. Kuriakose T, Kothari M, Paul P, Jacob P, Thomas R, Intracameral amphotericin B injection in the management of deep keratomycosis, Cornea, 2002, 21(7), 653-6.
37. Yilmaz S, Ture M, Maden A, Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis, Cornea, 2007, 26(4), 398-402.
38. Yoon K-C, Jeong I-Y, Im S-K, Chae H-J, Yang S-Y, Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis, Cornea, 2007, 26(7), 814-8.
39. Tejpal Y, Jat R, Microspheres as an ocular drug delivery systemâ€“A review, J Drug Deliv Therap, 2013, 3, 114-23.
40. Narang AS, Delmarre D, Gao D, Stable drug encapsulation in micelles and microemulsions, International journal of pharmaceutics, 2007, 345(1), 9-25.
41. Winsor P, Hydrotropy, solubilisation and related emulsification processes, Transactions of the Faraday Society, 1948, 44, 376-98.
42. Kaur IP, Kakkar S, Topical delivery of antifungal agents, Expert opinion on drug delivery, 2010, 7(11), 1303-27.
43. Honda M, Asai T, Oku N, Araki Y, Tanaka M, Ebihara N, Liposomes and nanotechnology in drug development: focus on ocular targets, International journal of nanomedicine, 2013, 8, 495.
44. Ali Y, Lehmussaari K, Industrial perspective in ocular drug delivery, Advanced drug delivery reviews, 2006, 58(11), 1258-68.
45. Amal El Sayeh F, Hassan MA, El-Maraghy DA, Ketorolac tromethamine floating beads for oral application: characterization and in vitro/in vivo evaluation, Saudi Pharmaceutical Journal, 2014, 22(4), 349-59.
46. Ghosh PK, Majithiya RJ, Umrethia ML, Murthy RS, Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability, AAPS PharmSciTech, 2006, 7(3), E172-E7.
47. Karasulu HY, Microemulsions as novel drug carriers: the formation, stability, applications and toxicity, Expert opinion on drug delivery, 2008, 5(1), 119-35.
48. Lawrence MJ, Rees GD, Microemulsion-based media as novel drug delivery systems, Advanced drug delivery reviews, 2000, 45(1), 89-121.
49. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW, Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound, Pharmaceutical research, 1992, 9(1), 87-93.
50. Chaudhari SP, Dave RH, To prepare and characterize microcrystalline cellulose granules using water and isopropyl alcohol as granulating agents and determine its end-point by thermal and rheological tools, Drug development and industrial pharmacy, 2015, 41(5), 744-52.
51. Abdulrazik M, Tamilvanan S, Khoury K, Benita S, Ocular delivery of cyclosporin A. II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A, STP pharma sciences, 2001, 11(6), 427-32.
52. Tamilvanan S, Khoury K, Gilhar D, Benita S, Ocular delivery of cyclosporin AI Design and characterization of cyclosporin A-loaded positively-charged submicron emulsion, STP pharma sciences, 2001, 11(6), 421-6.
53. Rawas-Qalaji M, Williams C-A, Advances in ocular drug delivery, Current eye research, 2012, 37(5), 345-56.
54. Chan J, El Maghraby GM, Craig JP, Alany RG, Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation, International journal of pharmaceutics, 2007, 328(1), 65-71.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).